OPK
OPKO Health Inc
$
1.250
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.320
Open
1.320
VWAP
1.26
Vol
3.59M
Mkt Cap
992.23M
Low
1.230
Amount
4.50M
EV/EBITDA(TTM)
--
Total Shares
696.99M
EV
1.07B
EV/OCF(TTM)
--
P/S(TTM)
1.33
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
138.88M
-7.35%
--
--
164.15M
-10.59%
--
--
161.62M
-6.9%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for OPKO Health, Inc. (OPK) for FY2025, with the revenue forecasts being adjusted by -3.59% over the past three months. During the same period, the stock price has changed by -0.79%.
Revenue Estimates for FY2025
Revise Downward
-3.59%
In Past 3 Month
Stock Price
Go Down
-0.79%
In Past 3 Month
5 Analyst Rating
131.20% Upside
Wall Street analysts forecast OPK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OPK is 2.89 USD with a low forecast of 1.00 USD and a high forecast of 5.20 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
1 Hold
0 Sell
Strong Buy
131.20% Upside
Current: 1.250
Low
1.00
Averages
2.89
High
5.20
131.20% Upside
Current: 1.250
Low
1.00
Averages
2.89
High
5.20
JPMorgan
Neutral
initiated
2025-04-25
Reason
JPMorgan
Price Target
2025-04-25
initiated
Neutral
Reason
JPMorgan initiated coverage of Opko Health with a Neutral rating and no price target. Following a series of asset sales and monetizing transactions, Opko is closing in on its goal of becoming a self-funded biotech company, the analyst tells investors in a research note. However, the firm believes it will take a series of clinical wins to gain broader investor recognition, with shares likely to trade range-bound over the mid-term.
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$3
2025-04-07
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$3
2025-04-07
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$3
2025-03-19
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$3
2025-03-19
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$3
2025-03-12
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$3
2025-03-12
Reiterates
Strong Buy
Reason
Barrington Research
Michael Petusky
Buy
Maintains
$2.25
2025-03-12
Reason
Barrington Research
Michael Petusky
Price Target
$2.25
2025-03-12
Maintains
Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$3
2025-03-03
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$3
2025-03-03
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for OPKO Health Inc (OPK.O) is -6.10, compared to its 5-year average forward P/E of 85.56. For a more detailed relative valuation and DCF analysis to assess OPKO Health Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
85.56
Current PE
-6.10
Overvalued PE
445.01
Undervalued PE
-273.90
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-18.06
Current EV/EBITDA
-13.29
Overvalued EV/EBITDA
20.22
Undervalued EV/EBITDA
-56.35
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
1.70
Current PS
1.60
Overvalued PS
2.09
Undervalued PS
1.31
Financials
Annual
Quarterly
FY2025Q2
YoY :
-13.93%
156.81M
Total Revenue
FY2025Q2
YoY :
-2.74%
-59.98M
Operating Profit
FY2025Q2
YoY :
+1340.62%
-148.44M
Net Income after Tax
FY2025Q2
YoY :
+1800.00%
-0.19
EPS - Diluted
FY2025Q2
YoY :
+157.65%
-86.70M
Free Cash Flow
FY2025Q2
YoY :
+11.49%
19.11
Gross Profit Margin - %
FY2025Q2
YoY :
+225.15%
-39.05
FCF Margin - %
FY2025Q2
YoY :
+1572.44%
-94.66
Net Margin - %
FY2025Q2
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
1
891.0K
USD
Months
3-6
5
1.1M
USD
Months
6-9
6
2.1M
USD
Months
0-12
4
1.1M
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 1498.79% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
1
891.0K
USD
Months
3-6
5
1.1M
USD
Months
6-9
6
2.1M
USD
Months
0-12
4
1.1M
USD
Months
OPK News & Events
Events Timeline
2025-06-25 (ET)
2025-06-25
08:06:40
Opko Health, Entera Bio say OPK-88006 data selected for ENDO 2025
2025-06-09 (ET)
2025-06-09
08:18:53
Opko Health's ModeX forms Scientific Advisory Board
2025-04-04 (ET)
2025-04-04
08:08:13
Opko Health board authorizes $100M increase to existing share repurchase program
Sign Up For More Events
Sign Up For More Events
News
9.5
08-07NASDAQ.COMOPKO Health (OPK) Q2 2025 Earnings Call Transcript
8.0
08-06Barron'sRFK Jr. Ordered the HHS to Stop Funding mRNA Vaccine Development. The Edict Hit a Biotech Working on an Unrelated Treatment.
4.0
08-01NASDAQ.COMValidea Kenneth Fisher Strategy Daily Upgrade Report - 8/1/2025
Sign Up For More News
People Also Watch
PGRE
Paramount Group Inc
6.410
USD
-0.31%
GOOS
Canada Goose Holdings Inc
11.210
USD
-2.01%
THR
Thermon Group Holdings Inc
24.100
USD
-3.41%
DLX
Deluxe Corp
19.140
USD
-0.36%
SEAT
Vivid Seats Inc
16.760
USD
-6.53%
BFC
Bank First Corp
116.450
USD
+0.78%
TIXT
TELUS International (CDA) Inc
3.790
USD
+2.43%
AHH
Armada Hoffler Properties Inc
6.950
USD
+0.29%
NXRT
NexPoint Residential Trust Inc
31.020
USD
-1.34%
PHVS
Pharvaris NV
20.120
USD
-0.98%
FAQ
What is OPKO Health Inc (OPK) stock price today?
The current price of OPK is 1.25 USD — it has increased 1.63 % in the last trading day.
What is OPKO Health Inc (OPK)'s business?
What is the price predicton of OPK Stock?
What is OPKO Health Inc (OPK)'s revenue for the last quarter?
What is OPKO Health Inc (OPK)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for OPKO Health Inc (OPK)'s fundamentals?
How many employees does OPKO Health Inc (OPK). have?